Skip to main content

Published locations for Ibrutinib plus obinutuzumab gets priority review in CLL/SLL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ibrutinib plus obinutuzumab gets priority review in CLL/SLL

User login

  • Reset your password
  • /content/ibrutinib-plus-obinutuzumab-gets-priority-review-cll/sll
  • /hematologynews/article/177465/cll/ibrutinib-plus-obinutuzumab-gets-priority-review-cll/sll
  • /oncologypractice/article/177465/cll/ibrutinib-plus-obinutuzumab-gets-priority-review-cll/sll
  • /hematologynews/nhlhub/article/177465/cll/ibrutinib-plus-obinutuzumab-gets-priority-review-cll/sll
  • /hematology-oncology/article/177465/cll/ibrutinib-plus-obinutuzumab-gets-priority-review-cll/sll
  • /b-cell-lymphoma-icymi/article/177465/cll/ibrutinib-plus-obinutuzumab-gets-priority-review-cll/sll